Long-term results of peripheral arterial disease rehabilitation
- PMID: 15192556
- DOI: 10.1016/j.jvs.2004.01.034
Long-term results of peripheral arterial disease rehabilitation
Abstract
Purpose: Although the Peripheral Arterial Disease Rehabilitation Program (PADRx) improves walking ability and quality of life over brief periods of follow-up, the long-term durability of results has not been established. This study examined functional status, walking ability, and quality of life in patients several months after completion of a 12-week PADRx.
Methods: Patients who completed a PADRx were eligible for participation. A Medical Outcomes Study 36-Item Short Form (SF-36), Walking Impairment Questionnaire (WIQ), and physical activity questionnaire were administered by telephone. A progressive treadmill test was performed on-site.
Results: Of 63 eligible patients, 14 were lost to follow-up, 11 refused participation, and four died. Thirty-four patients had completed PADRx 20 to 80 months previously (mean, 48.2 +/- 13.7 months), and completed the phone survey. Fifteen patients reported exercising a minimum of 60 min/wk for 3 months (EX group), and 19 had not exercised in the preceding 3 months (SED group). Self-reported SF-36 values were significantly different between the EX and SED groups for Physical Function (43.3 +/- 8.2 vs 34.2 +/- 7.8), Role-Physical Function (41.2 +/- 7.7 vs 32.8 +/- 9.2), and Bodily Pain (46.9 +/- 8.8 vs 38.9 +/- 7.1), as well as the Physical Composite (43.5 +/- 6.5 vs 34.0 vs 5.8) domains of the SF-36. Similarly the WIQ demonstrated significant differences in Walking Distance (46.8 +/- 36.2 vs 7.8 +/- 9.4), Walking Speed (47.5 +/- 32.6 vs 14.5 +/- 13.9), and Stair Climbing (60.6 +/- 36.6 vs 37.1 +/- 27.6), favoring the EX group. Sixteen patients, equally distributed between the EX and SED groups, completed the progressive treadmill test. Both groups had experienced improvement (P <.05) in claudication pain time and maximal walking time after completing the 12-week supervised program. The EX group maintained increased claudication pain time of 121% and maximum walking time of 109% over baseline, whereas the SED group values had returned to baseline (P <.05).
Conclusions: Patients with claudication realize symptomatic and functional improvement with supervised exercise programs. Those who continue to exercise will potentially maintain these benefits and experience improved health-related quality of life.
Similar articles
-
Claudication distances and the Walking Impairment Questionnaire best describe the ambulatory limitations in patients with symptomatic peripheral arterial disease.J Vasc Surg. 2008 Mar;47(3):550-555. doi: 10.1016/j.jvs.2007.10.052. Epub 2008 Jan 22. J Vasc Surg. 2008. PMID: 18207355
-
Improving walking ability and ankle brachial pressure indices in symptomatic peripheral vascular disease with intermittent pneumatic foot compression: a prospective controlled study with one-year follow-up.J Vasc Surg. 2000 Apr;31(4):650-61. doi: 10.1067/mva.2000.103969. J Vasc Surg. 2000. PMID: 10753272 Clinical Trial.
-
Effects of a long-term exercise program on lower limb mobility, physiological responses, walking performance, and physical activity levels in patients with peripheral arterial disease.J Vasc Surg. 2008 Feb;47(2):303-9. doi: 10.1016/j.jvs.2007.10.038. J Vasc Surg. 2008. PMID: 18241753 Clinical Trial.
-
A meta-analysis of the outcome of endovascular and noninvasive therapies in the treatment of intermittent claudication.J Vasc Surg. 2011 Nov;54(5):1511-21. doi: 10.1016/j.jvs.2011.06.106. Epub 2011 Sep 29. J Vasc Surg. 2011. PMID: 21958561 Review.
-
Established and evolving medical therapies for claudication in patients with peripheral arterial disease.Nat Clin Pract Cardiovasc Med. 2006 Nov;3(11):604-10. doi: 10.1038/ncpcardio0660. Nat Clin Pract Cardiovasc Med. 2006. PMID: 17063165 Review.
Cited by
-
Effects of a 6-month exercise program pilot study on walking economy, peak physiological characteristics, and walking performance in patients with peripheral arterial disease.Vasc Health Risk Manag. 2012;8:225-32. doi: 10.2147/VHRM.S30056. Epub 2012 Apr 17. Vasc Health Risk Manag. 2012. PMID: 22566743 Free PMC article. Clinical Trial.
-
Durability of Benefits From Supervised Treadmill Exercise in People With Peripheral Artery Disease.J Am Heart Assoc. 2019 Jan 8;8(1):e009380. doi: 10.1161/JAHA.118.009380. J Am Heart Assoc. 2019. PMID: 30587066 Free PMC article. Clinical Trial.
-
Percutaneous treatment of peripheral vascular disease: the role of diabetes and inflammation.J Vasc Surg. 2007 Jun;45 Suppl A(Suppl A):A149-57. doi: 10.1016/j.jvs.2007.02.029. J Vasc Surg. 2007. PMID: 17544036 Free PMC article. Review.
-
Peripheral arterial disease affects the frequency response of ground reaction forces during walking.Clin Biomech (Bristol). 2012 Dec;27(10):1058-63. doi: 10.1016/j.clinbiomech.2012.08.004. Epub 2012 Sep 9. Clin Biomech (Bristol). 2012. PMID: 22967739 Free PMC article.
-
Telmisartan improves absolute walking distance and endothelial function in patients with peripheral artery disease.Clin Res Cardiol. 2010 Dec;99(12):787-94. doi: 10.1007/s00392-010-0184-0. Epub 2010 Jul 8. Clin Res Cardiol. 2010. PMID: 20614124 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources